Downstream Processing Featured Articles

  1. GE Healthcare Launches FF High Performance Nitrocellulose Membranes Optimized For Diagnostic Assay Reproducibility 8/1/2012

    GE Healthcare Life Sciences’ new Whatman FF High Performance (HP) membrane provides the industry with a new diagnostic membrane to enable fast, razor-sharp line separation and highly reproducible results for the detection of target molecules in liquids such as water, urine, blood and saliva.

  2. Population Genetics Validates GenomePooling For Cancer 7/31/2012

    Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

  3. GE Healthcare Launches New Modular Chromatography System For Protein Purification 9/5/2012

    GE Healthcare launches the of ÄKTA™ pure, a chromatography system for flexible, reliable and intuitive purification of proteins with the flexibility to support both routine and challenging purification requirements, as well as being adaptable to changing research needs. 

  4. Samsung Bioepis And MSD Enter Biosimilars Development And Commercialization Agreement 2/20/2013

    Samsung Bioepis Co., Ltd. and MSD, known as Merck in the United States and Canada, announced
    today they have entered into an agreement to develop and commercialize multiple pre-
    specified and undisclosed biosimilar candidates.

  5. CellCentric And ZoBio Enter Into Partnership To Develop Lead Compounds Against Epigenetic Drug Targets 6/20/2012

    ZoBio and CellCentric are pleased to announce that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.

  6. Ablynx's Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety And Efficacy Results In A Phase II Clinical Trial In Rheumatoid Arthritis 2/13/2013

    Ablynx (EURONEXT BRUSSELS: ABLX) today announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week final analysis of the Phase II part of a combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.

  7. Innate Pharma Presents New Data For Proprietary Programs Targeting TLR3 And KIR3DL2 4/15/2013

    Innate Pharma SA (EURONEXT PARIS: IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for two proprietary programs were presented at the Molecular Pattern Recognition Receptors meeting and the American Association for Cancer Research ("AACR") annual meeting.

  8. Avanti J-26S High Performance Centrifuge Provides Enhanced Environmental, Safety Benefits 8/8/2012

    The newly redesigned Avanti J-26S high performance centrifuge from Beckman Coulter Life Sciences combines important environmental benefits with increased BioSafety* features.

  9. Saint-Gobain's New C-Flex® ULTRA Pump Tubing For Biopharmaceutical Applications Outperforms The Competition 6/28/2012

    Saint-Gobain Performance Plastics has expanded its line of thermoplastic elastomer (TPE) tubing with the addition of new C-Flex® ULTRA pump tubing, a product designed specifically to perform in demanding biopharmaceutical applications such as pumping, single-use assemblies, process filling and sampling.

  10. The Medicines Company And Bristol-Myers Squibb Begin Global Alliance For Recothrom® 2/8/2013

    The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom®, a recombinant thrombin approved by the U.S.